These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34430353)

  • 1. Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.
    Sato Y; Watanabe S; Ota T; Kushiro K; Fujisaki T; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Hayashi M; Ishikawa H; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Ohshima Y; Koya T; Kikuchi T
    Transl Lung Cancer Res; 2021 Jul; 10(7):3132-3143. PubMed ID: 34430353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
    Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
    Front Oncol; 2021; 11():704475. PubMed ID: 34631533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management.
    Kim S; Lim JU
    J Thorac Dis; 2022 May; 14(5):1684-1695. PubMed ID: 35693611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
    Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
    Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
    Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Tasaka Y; Honda T; Nishiyama N; Tsutsui T; Saito H; Watabe H; Shimaya K; Mochizuki A; Tsuyuki S; Kawahara T; Sakakibara R; Mitsumura T; Okamoto T; Kobayashi M; Chiaki T; Yamashita T; Tsukada Y; Taki R; Jin Y; Sakashita H; Natsume I; Saitou K; Miyashita Y; Miyazaki Y
    Lung Cancer; 2021 May; 155():120-126. PubMed ID: 33798901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study.
    Suzuki Y; Karayama M; Uto T; Fujii M; Matsui T; Asada K; Kusagaya H; Kato M; Matsuda H; Matsuura S; Toyoshima M; Mori K; Ito Y; Koyauchi T; Yasui H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
    J Thorac Oncol; 2020 Aug; 15(8):1317-1327. PubMed ID: 32289515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
    Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
    JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.
    Watanabe S; Ota T; Hayashi M; Ishikawa H; Otsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Miyabayashi T; Miura S; Tanaka H; Abe T; Okajima M; Terada M; Ishida T; Iwashima A; Sato K; Yoshizawa H; Kikuchi T
    Cancer Med; 2020 May; 9(9):3070-3077. PubMed ID: 32150668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
    Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
    Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
    Kanai O; Kim YH; Demura Y; Kanai M; Ito T; Fujita K; Yoshida H; Akai M; Mio T; Hirai T
    Thorac Cancer; 2018 Jul; 9(7):847-855. PubMed ID: 29782069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
    Suzuki K; Yanagihara T; Matsumoto K; Kusaba H; Yamauchi T; Ikematsu Y; Tanaka K; Otsubo K; Inoue H; Yoneshima Y; Iwama E; Arimura-Omori M; Harada E; Hamada N; Okamoto I; Nakanishi Y
    Int Immunol; 2020 Jul; 32(8):547-557. PubMed ID: 32253426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.